Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy

被引：2

作者：

Eide, Christopher A. ^{[1
]}

Brewer, Diana ^{[1
]}

Xie, Tao ^{[2
]}

Schultz, Anna Reister ^{[1
]}

Savage, Samantha L. ^{[1
]}

Muratcioglu, Serena ^{[3
]}

Merz, Noah ^{[1
]}

Press, Richard D. ^{[4
]}

O'Hare, Thomas ^{[5
]}

Jacob, Thomas ^{[6
]}

Vu, Tania Q. ^{[6
,7
]}

Tognon, Cristina E. ^{[1
]}

Macey, Tara A. ^{[1
]}

Kuriyan, John ^{[3
,8
]}

Kalodimos, Charalampos G. ^{[2
]}

Druker, Brian J. ^{[1
]}

机构：

[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97239 USA

[2] St Jude Childrens Res Hosp, Dept Struct Biol, Memphis, TN USA

[3] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN USA

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Pathol, Portland, OR USA

[5] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[6] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR USA

[7] Oregon Hlth & Sci Univ, Ctr Spatial Syst Biosci, Portland, OR USA

[8] Vanderbilt Coll Arts & Sci, Dept Chem, Nashville, TN USA

来源：

CANCER CELL | 2024年 / 42卷 / 09期

关键词：

PROTEIN;

D O I：

10.1016/j.ccell.2024.08.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1486 / 1488

页数：3

共 50 条

[31] A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia
Lim, Ye Seul
Jeong, Na-Rae
Yoo, Sun-Mi
Kim, Han Wool
Lee, Song Hee
Kim, Dong-Wook
BLOOD, 2023, 142
[32] BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation
Alikian, Mary
Gerrard, Gareth
Subramanian, Papagudi G.
Mudge, Katherine
Foskett, Pierre
Khorashad, Jamshid Sorouri
Lim, Ai Chiin
Marin, David
Milojkovic, Dragana
Reid, Alistair
Rezvani, Katy
Goldman, John
Apperley, Jane
Foroni, Letizia
AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (03) : 298 - 304
[33] Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1T315I-compound mutations
Gleixner, Karoline, V
Filik, Yuksel
Berger, Daniela
Schewzik, Christina
Stefanzl, Gabriele
Sadovnik, Irina
Degenfeld-Schonburg, Lina
Eisenwort, Gregor
Schneeweiss-Gleixner, Mathias
Byrgazov, Konstantin
Sperr, Wolfgang R.
Mayer, Jiri
Lion, Thomas
Valent, Peter
AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (09): : 4470 - 4484
[34] Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
M S Zabriskie
N A Vellore
K C Gantz
M W Deininger
T O'Hare
Leukemia, 2015, 29 : 1939 - 1942
[35] Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib
Hall, Kevin H.
Brooks, Angelique
Waller, Edmund K.
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (08) : E293 - E295
[36] Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
Zabriskie, M. S.
Vellore, N. A.
Gantz, K. C.
Deininger, M. W.
O'Hare, T.
LEUKEMIA, 2015, 29 (09) : 1939 - 1942
[37] A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
Montecchini, Oksana
Braidotti, Stefania
Franca, Raffaella
Zudeh, Giulia
Boni, Christian
Sorio, Claudio
Toffoletti, Eleonora
Rabusin, Marco
Tommasini, Alberto
Decorti, Giuliana
Stocco, Gabriele
FRONTIERS IN PHARMACOLOGY, 2021, 12
[38] GilteritinibDrug resistance secondary to acquisition of BCR-ABL1 mutation: case report
Reactions Weekly, 2020, 1819 (1) : 131 - 131
[39] Detection of ABL1 kinase Domain Mutations in Therapy Naive BCR-ABL1 Positive ALL
Baer, Constance Regina
Meggendorfer, Manja
Haferlach, Claudia
Kern, Wolfgang
Haferlach, Torsten
BLOOD, 2017, 130
[40] Comparison Of BCR-ABL1/ABL1 and BCR-ABL1/GUS Ratios At Different Clinical Decision Cut-Offs In Chronic Phase Chronic Myelogenous Leukemia Patients On Imatinib
Huet, Sarah
Souche, Denis
Magaud, Jean-Pierre
Cony-Makhoul, Pascale
Guillermin, Yann
Heiblig, Mael
Michallet, Mauricette
Nicolini, Franck E.
Hayette, Sandrine
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →